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observed that the orphan designation system in Japan has achieved certain results for 
increasing the accessibility of necessary drugs to patients suffering with rare diseases. 
However, several drugs are still not available in Japan, partly because of the difference 
in deﬁ nitions of orphan disease among the 3 regions. To increase the accessibility to 
orphan drugs, further policy interventions should be considered.
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OBJECTIVES: There is a continuous problem in Hungary—and assumable in many 
other countries—with planning the health insurance pharmaceutical budget. In 
Hungary there is a substantial gap between the planned and the actual budget resulting 
in an overspending of the planned pharmaceutical budget. The aim of our study is to 
analyze the gap between the planned and the actual health insurance pharmaceutical 
budget. METHODS: Data were derived from the nationwide administrative data set 
of the National Health Insurance Fund Administration (OEP), the only health care 
ﬁ nancing agency in Hungary. We analyzed the difference between the planned and 
the actual pharmaceutical budget of OEP between 1994 and 2006. Outcome (over-
spending rate) is measured with the following formula: the difference between the 
planned and the actual budget is divided with the planned budget. RESULTS: During 
the period of 1994–2006 we found signiﬁ cant overspending of pharmaceutical budget 
of OEP which varied between 3.4–36.6% of actual pharmaceutical expenditures. The 
peak of overspending showed a 4 years circle with the highest ﬁ gures in 1994 (21,5%), 
1998 (32.1%), 2002 (36.6%) and 2006 (30.4%). These 4 calendar years correspond 
with the time of national political (parliamentary) elections. CONCLUSIONS: We 
found the highest overspending of the Hungarian pharmaceutical budget in the years 
of national political elections. It is a scientiﬁ c evidence for the political inﬂ uence of 
the health insurance pharmaceutical budget. The overspending does not relate to any 
speciﬁ c political parties or governments because it was a general phenomenon in 
Hungary between 1994–2006.
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BACKGROUND: The Greek economy is being called upon to manage one of the 
highest proportions of public debt versus GDP in the European Union and the Euro 
zone. In turn, the health care sector is subject to the distortions of the Greek public 
sector, as there is no ofﬁ cial method of measuring and evaluating the services being 
provided. OBJECTIVES: The objective of this analysis was both to interpret the 
development of pharmaceutical expenditure, based on the most signiﬁ cant changes in 
the pricing and reimbursement system, as well as to evaluate the institutional changes 
based on their effectiveness. METHODS: The analysis reﬂ ects the evolution of phar-
maceutical expenditure and interprets the changes in the regulatory framework that 
took place in Greece from 1998–2008. It should be noted that there is signiﬁ cant 
confusion around the actual level of pharmaceutical expenditure, as the data provided 
for 2003–2007 (provisional data) from the National Statistical Service of Greece are 
not in agreement with OECD’s data. Following a more careful analysis of the data, 
numerous questions arise with respect to their reliability, as there is no explanation 
for the apparent rate of change with regard to the factors that could inﬂ uence expen-
diture (e.g. changes in the pricing or reimbursement system). Therefore the actual level 
of pharmaceutical expenditure is also in question. RESULTS: After analyzing the price 
changes in the top 100 selling pharmaceutical products in Greece, throughout the 
indicated period, it became obvious that the cause of increasing pharmaceutical 
expenditure cannot be attributed to increasing prices, but to other factors mainly 
associated with over-consumption. CONCLUSIONS: Finally, taking into account the 
intense pressures on public ﬁ nancing of the health care system, it is important for any 
future measures to constrain costs to be based on reliable and accurate data and to 
target the entirety of the system.
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OBJECTIVES: The Slovak guidelines for economic evaluation, although appearing to 
be generic, have been written focusing on pharmaceuticals. The objective of this study 
was to analyze the quality of submitted economic studies and related critical appraisals 
process and to develop a policy-relevant, publicly available Slovak critical appraisal 
checklist for improving the quality of economic evaluation for reimbursement submis-
sion of dossiers concerning to medical devices. METHODS: We created a working 
group to review previously submitted economic evaluations and related critical 
appraisals in order to identify potential technical and methodological problems. The 
working group consisted of two independent academic experts who scrutinized previ-
ous submissions and critical appraisals concerning to medical devices between 2007–
2010. RESULTS: Evidence suggests that the methods of economic evaluation can be 
equally applied to drugs and devices in general. However, there are several speciﬁ c 
methodological issues that require more attention if reliable and informative evalua-
tions of devices are to be conducted. These issues are underestimated within the Slovak 
Republic. It is well known that expenditures for medical devices do not result in the 
most cost-effective outcomes. Economic evaluations of medical devices are mandatory 
but the quality of evaluations and critical appraisals are poor. Our analysis shows that 
the simpliﬁ ed questionnaire, which is currently used for the critical appraisal process 
within Slovakia should be replaced by a new Slovak critical appraisal checklist, which 
will be detailed enough to address the speciﬁ c problems in the local economic evalu-
ations process. CONCLUSIONS: The transparent method of technology assessment 
can improve the consistency of reimbursement decisions making related to medical 
devices in Slovakia. Therefore in addition to the available Slovak health economic 
evaluation guidelines a detailed checklist for appraisal processes speciﬁ c for medical 
devices have to be prepared. The economic evaluation of devices raises additional 
challenges and the current Slovak guidelines overlook several issues.
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OBJECTIVES: The French cohort ATU provides early access to medicines for serious 
or rare diseases prior to marketing authorization (MA) for groups of patients. This 
study determines the length of time of patient access before MA for different types 
and classes of products subject to a cohort ATU. METHODS: All medicines subject 
to a cohort ATU between 1994 and 2009 were obtained from the website of Afssaps. 
Products which were never authorized were excluded. Time from initiation of a cohort 
ATU to marketing authorization was determined. Subgroup analyses were performed 
for orphan products, products developed by small and medium enterprises (SMEs), 
and products in major indication classes. RESULTS: 87 products matched the inclu-
sion criteria. Products were available on average 23 (range 0–121) months prior to 
MA. Orphan drugs (N = 13;15%) and non-orphan drugs were available 19 months 
(2–74) and 24 (0–121) months before MA respectively. Drugs developed by SMEs (N 
= 5;6%) were available on average 34 (9–59) months before MA, while drugs devel-
oped by larger companies were available 22 (0–121) months before MA. Blood 
products (ATC = B;N = 10;11%) were available on average 53 (2–121) months before 
MA, and anti-infectives (ATC = J;N = 31;36%) 15 (0–70) months, followed by 13 
(1–74) months for oncology products (ATC = L;N = 19;21%). The average length of 
time before MA decreased from 21.4 between 1994 and 2003 to 3.7 between 2004 
and 2008. CONCLUSIONS: This study demonstrates that the cohort ATU provides 
access to medicines several months before MA and has been used primarily by larger 
pharmaceutical companies. The length of time of access before MA differs by indica-
tion and type of product and has been shorter in recent years. Price level and indication 
should reﬂ ect future authorized indications and price. The lower than expected 
number of orphan drugs subject to a cohort ATU may be the result of more frequent 
use via the nominative ATU or in clinical trials.
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OBJECTIVES: To gather insights into global (5EU, US, emerging markets) national 
policy & key decision-makers’ beliefs & perceptions on current and future landscape 
as well as impact and value of telehealth/telemedicine initiatives within health care 
programmes from health economic perspectives. METHODS: Both primary and sec-
ondary research was used for this study. Literature reviews with compilation of all 
relevant and up-to-date information including data in local languages. Primary 
research focused on market speciﬁ cs where clariﬁ cation and market insights were 
required (such as MOH, budget-holder’s organizations, Public Health Institutions, 
senior health care professionals). RESULTS: Beneﬁ ts for improving both accessibility 
and quality of health care through telehealth/telemedicine have vast potential. These 
initiatives require substantial investment, whereas human and ﬁ nancial resources are 
limited. It is important to demonstrate economic viability, in addition to technical and 
clinical evaluations, in order to understand the optimal conditions under which new 
telehealth/telemedicine programmes should be unfolded. Traditionally, cost-effective-
ness analysis is used to evaluate telehealth/telemedicine programmes. Such an approach 
is represented only by monetary differentials (ﬁ xed, variable, marginal, and direct and 
indirect costs) and has numerous limitations due to the lack of available data as well 
as constant changes in technological progress. As discovered, it is imperative to add 
a range of different analytical techniques to traditional cost analyses. Other factors—
such as perception and investment choices, quality of health care provision, consumer 
choice and political environment—should be taken into consideration. CONCLU-
SIONS: To understand the criteria national leaders use, and the supporting evidence 
they require, to allocate monetary resources for innovative telehealth/telemedicine 
programmes—traditional monetary analysis is not enough and we recommend two 
supplementary approaches: societal and perceptual analysis. This will allow further 
insights on views and value that telehealth/telemedicine initiatives deliver—and the 
priority within health care programmes—in order to reveal the willingness to pay 
among key decision-makers.
